Aprea Therapeutics (NASDAQ:APRE) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Aprea Therapeutics (NASDAQ:APRE) issued its earnings results on Monday. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.05, Yahoo Finance reports. The company had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.10 million. Aprea Therapeutics had a negative net margin of 1,317.82% and a negative return on equity of 56.78%.

Aprea Therapeutics Trading Down 0.3 %

Shares of APRE stock traded down $0.01 on Tuesday, reaching $3.21. The company had a trading volume of 107 shares, compared to its average volume of 19,850. The stock has a market cap of $17.43 million, a PE ratio of -0.97 and a beta of 1.04. The company has a 50-day moving average of $3.98 and a 200-day moving average of $5.28. Aprea Therapeutics has a 12 month low of $3.20 and a 12 month high of $8.85.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on APRE shares. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a research report on Monday. Wedbush reiterated an “outperform” rating and set a $11.00 price target on shares of Aprea Therapeutics in a research report on Tuesday, May 14th.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.